Airway Therapeutics’ Investigational New Drug (IND) application to develop AT-100 (rhSP-D) as a treatment for COVID-19 has been accepted by the FDA. Airway is leveraging the FDA’s Coronavirus Treatment Acceleration Program (CTAP) aimed at evaluating new treatment options for COVID-19.   Airway will initiate a Phase 1b clinical trial to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.   Airway’s novel human reco...